Nasdaq:US$12.00 (-0.07) | HKEX:HK$19.00 (-0.90) | AIM:£1.93 (-0.05)
Search Result
Previous Article   |   Next Article
Scientific Publications | 3 Nov 2021

NANETS 2021: Interim Analysis Results of Surufatinib in US Patients with Neuroendocrine Tumors